Navigation Links
Focused Treatment For Childhood Cancer

A poorly understood type of childhood brain cancer has a unique molecule signature that may point to which therapies could best fight it.// Armed with targeted molecular treatments, doctors may be able to fight the disease without risking the side effects of prolonged and powerful radiation and chemotherapy at an early age.

The latest research is a collaborative effort looking at a type of childhood tumour known as medulloblastoma, the most common childhood tumour of the CNS. The cancer usually strikes between the ages of 5 and 10. Medulloblastomas are highly malignant, and can spread to the spine and other parts of the body. But over the past few decades, refined treatments have increased survival rates until approximately 80 percent of children survive for five to 10 years after diagnosis.

But the therapies aren't perfect. Radiation and chemotherapy for up to a year at such a young age can lead to hearing loss, cataracts and severe learning disabilities that can leave children unable to live independently in later life.

Led by Dr. Scott Pomeroy, an associate professor of neurology at Children's Hospital in Boston, the researchers found that increased activity of Sonic Hedgehog (SHH), a signaling molecule crucial to brain development, is linked to one type of medulloblastoma. "As compared to chemotherapy, which is non-specific and damages all cells … these very focused treatments will only work on those tumors that have that particular molecular pathway active," says Pomeroy.

Recently developed compounds that can block the uncontrolled SHH signaling found in the tumors could potentially be used as a therapy in children with medulloblastoma. Researchers also found that the clinical outcome of an individual child's struggle with medulloblastoma could be accurately predicted by examining the patterns of gene expression in the cancer at the time of diagnosis.
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Inadequate Drug Treatment For Youth
9. FDA Approves New surgery Treatment for Farsightedness
10. Treatment of antibiotics ineffectual in bronchitis
11. Oxygen Treatment may be injurious
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2019)... ... June 24, 2019 , ... ... today announced the restructuring of the Strategic Advisory Board (SAB) to help inform ... demand for behavioral health care. , We are honored to announce ...
(Date:6/20/2019)... , ... June 20, 2019 , ... ... portfolio company of Chicago Pacific Founders, announced a strategic partnership with Northern Westchester ... partnership expands SightMD’s leading position in New York, adding the Company’s first location ...
(Date:6/19/2019)... , ... June 19, 2019 , ... ... demonstrated their ability to meet rigorous national standards of performance continues to climb. ... national initial accreditation status to 11 local governmental public health departments. With this ...
(Date:6/19/2019)... ... June 19, 2019 , ... ... International Research Congress (IRC) in Marseille, France. The conference is widely seen ... on facioscapulohumeral muscular dystrophy (FSHD). Nearly 200 researchers, clinicians, industry representatives and patient ...
(Date:6/18/2019)... SEATTLE (PRWEB) , ... June 18, 2019 , ... ... company developing non-invasive treatments for cancers and other serious diseases, announced it has ... the EMulate Therapeutics application for Humanitarian Device Exemption (HDE) for the Hælo Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/25/2019)... (PRWEB) , ... June 25, 2019 , ... ... with a vast amount of experience as most of the Baby Boomers who ... published 2018 ASCP Vacancy Survey report. , While overall retirement rates are at ...
(Date:6/24/2019)... ... June 24, 2019 , ... The Conference Forum has announced ... place on September 17-18, 2018 at the Renaissance Waterfront Hotel in Boston, MA, with ... Scott Gottlieb, 23rd Commissioner of the FDA, has chosen DPharm to deliver his perspective ...
(Date:6/24/2019)... (PRWEB) , ... June 24, 2019 , ... ... protective equipment designed to provide breathability and comfort for the electrical industry has ... commitment to worker safety. , The guide, titled Developing a Culture of ...
Breaking Medicine Technology: